Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
358 EUR | +1.13% | -0.56% | -0.42% |
May. 03 | VIRBAC : Virbac remains an attractive animal healthcare play | |
Apr. 17 | VIRBAC : A healthy start to 2024; outlook re-iterated |
Sales 2024 * | 1.38B 1.49B | Sales 2025 * | 1.48B 1.6B | Capitalization | 3B 3.25B |
---|---|---|---|---|---|
Net income 2024 * | 139M 151M | Net income 2025 * | 155M 168M | EV / Sales 2024 * | 2.23 x |
Net Debt 2024 * | 74.94M 81.27M | Net cash position 2025 * | 43.1M 46.74M | EV / Sales 2025 * | 2 x |
P/E ratio 2024 * |
21.6
x | P/E ratio 2025 * |
19.5
x | Employees | 5,459 |
Yield 2024 * |
0.41% | Yield 2025 * |
0.45% | Free-Float | 48.71% |
Latest transcript on Virbac
1 day | +1.13% | ||
1 week | -0.56% | ||
1 month | +3.17% | ||
3 months | +5.60% | ||
6 months | +24.74% | ||
Current year | -0.42% |
Managers | Title | Age | Since |
---|---|---|---|
Sébastien Huron
CEO | Chief Executive Officer | 54 | 05-12-31 |
Habib Ramdani
DFI | Director of Finance/CFO | 48 | 16-01-31 |
Sophie Favini
COO | Chief Operating Officer | - | 23-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philippe Capron
BRD | Director/Board Member | 65 | 03-12-31 |
Chairman | 59 | 97-12-31 | |
Director/Board Member | 63 | 94-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.25% | 1 M€ | -.--% | ||
0.02% | 746 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 358 | +1.13% | 6,717 |
24-05-30 | 354 | +0.85% | 2,676 |
24-05-29 | 351 | -0.28% | 2,212 |
24-05-28 | 352 | -2.22% | 2,673 |
24-05-27 | 360 | -.--% | 843 |
Real-time Euronext Paris, May 31, 2024 at 11:35 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-0.42% | 3.25B | |
-14.09% | 77.37B | |
+18.66% | 8.74B | |
+23.75% | 3.67B | |
+18.07% | 1.73B | |
-16.99% | 1.38B | |
-26.05% | 1.24B | |
-17.86% | 1.07B | |
-6.77% | 976M | |
-2.89% | 892M |
- Stock Market
- Equities
- VIRP Stock